Stocks News

LAST PRICE
99.3800
TODAY'S CHANGE (%)
Trending Up0.6000 (0.6074%)

Bid / Lots
50.4700/ 5
Ask / Lots
107.0000/ 1
Open / Previous Close
99.7300 / 98.7800
Day Range
Low 98.4000
High 101.0050
52 Week Range
Low 49.2400
High 112.1250
Volume
90,517
below average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

Sep 6, 2024
- Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI(R) (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy, from 9:20AM ET on Friday Sep 06, 2024 by Dow Jones
  9:20AM ET on Friday Sep 06, 2024 by Dow Jones
  Companies Mentioned: LGND
  
  the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
  
  View source version on businesswire.com: https://www.businesswire.com/news/home/20240906026028/en/

Yesterday
- Harrow to Expand Corporate Headquarters in Nashville, from 12:31PM ET on Wednesday Sep 25, 2024 by MT Newswires
  12:31PM ET on Wednesday Sep 25, 2024 by MT Newswires
  Companies Mentioned: HROW
- Harrow Announces Nashville Expansion, from 12:02PM ET on Wednesday Sep 25, 2024 by Dow Jones
  12:02PM ET on Wednesday Sep 25, 2024 by Dow Jones
  Companies Mentioned: HROW
- Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ(TM) (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent, from 8:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
  8:00AM ET on Wednesday Sep 25, 2024 by Dow Jones
  Companies Mentioned: AVDL
- Ocular Therapeutix(TM) to Present at the UBS Virtual Opthalmology Day 2024, from 7:30AM ET on Wednesday Sep 25, 2024 by Dow Jones
  7:30AM ET on Wednesday Sep 25, 2024 by Dow Jones
  Companies Mentioned: OCUL
Sep 17, 2024
- DJ Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:21AM ET on Tuesday Sep 17, 2024 by Dow Jones
  6:21AM ET on Tuesday Sep 17, 2024 by Dow Jones
  Companies Mentioned: IMCR
- DJ Immunocore Holdings Is Maintained at Buy by Needham, from 6:04AM ET on Tuesday Sep 17, 2024 by Dow Jones
  6:04AM ET on Tuesday Sep 17, 2024 by Dow Jones
  Companies Mentioned: IMCR
Sep 14, 2024
- Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer, from 3:00AM ET on Saturday Sep 14, 2024 by Dow Jones
  3:00AM ET on Saturday Sep 14, 2024 by Dow Jones
  Companies Mentioned: IMCR
Sep 12, 2024
- Immunocore to present at the 2024 Cantor Global Healthcare Conference, from 7:31PM ET on Thursday Sep 12, 2024 by GlobeNewswire
  7:31PM ET on Thursday Sep 12, 2024 by GlobeNewswire
  Companies Mentioned: IMCR
- Immunocore to present at the 2024 Cantor Global Healthcare Conference, from 4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
  4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
  Companies Mentioned: IMCR
- Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
  4:05PM ET on Thursday Sep 12, 2024 by Dow Jones
  Companies Mentioned: OCUL

Ligand Pharmaceuticals Inc
NASDAQ:LGNDUnited States

Search Criteria

Sep 6, 2024

Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI(R) (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy, from 9:20AM ET on Friday Sep 06, 2024 by Dow Jones

Peers Headlines

Yesterday

Harrow to Expand Corporate Headquarters in Nashville, from 12:31PM ET on Wednesday Sep 25, 2024 by MT Newswires

Harrow Announces Nashville Expansion, from 12:02PM ET on Wednesday Sep 25, 2024 by Dow Jones

Avadel Pharmaceuticals Announces Publication of Data Highlighting Efficacy of LUMRYZ(TM) (sodium oxybate) Extended-Release Oral Suspension in Improving Narcolepsy Symptoms Regardless of Concomitant Use of an Alerting Agent, from 8:00AM ET on Wednesday Sep 25, 2024 by Dow Jones

Ocular Therapeutix(TM) to Present at the UBS Virtual Opthalmology Day 2024, from 7:30AM ET on Wednesday Sep 25, 2024 by Dow Jones

Sep 17, 2024

DJ Immunocore Holdings Price Target Maintained With a $100.00/Share by HC Wainwright & Co., from 6:21AM ET on Tuesday Sep 17, 2024 by Dow Jones

DJ Immunocore Holdings Is Maintained at Buy by Needham, from 6:04AM ET on Tuesday Sep 17, 2024 by Dow Jones

Sep 14, 2024

Immunocore presents Phase 1 data of brenetafusp, an ImmTAC bispecific targeting PRAME, in patients with ovarian cancer, from 3:00AM ET on Saturday Sep 14, 2024 by Dow Jones

Sep 12, 2024

Immunocore to present at the 2024 Cantor Global Healthcare Conference, from 7:31PM ET on Thursday Sep 12, 2024 by GlobeNewswire

Immunocore to present at the 2024 Cantor Global Healthcare Conference, from 4:05PM ET on Thursday Sep 12, 2024 by Dow Jones

Ocular Therapeutix(TM) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4), from 4:05PM ET on Thursday Sep 12, 2024 by Dow Jones